论文部分内容阅读
目的观察重组人血管内皮抑素注射液(恩度)联合化疗治疗晚期肺腺癌的安全性。方法选择经病理组织学或细胞学检查确诊的晚期肺腺癌患者24例。将重组人血管内皮抑素注射液15 mg加入生理盐水500 mL中匀速缓慢静脉滴注,第1~14天连续给药,间歇7 d重复,同时联合NP化疗药物每21 d为1个周期。用药2周期后评价不良反应和疗效。结果全组24例患者用药2个周期后,其中完全缓解(CR)0例,部分缓解(PR)7例(29%),稳定(SD)13例(54%),进展(PD)4例(17%)。有效率(RR)29%,临床获益83%;出现Ⅲ级的不良反应4例,包括消化道反应(1/24)和血小板减少(3/24)。结论重组人血管内皮抑素注射液联合NP化疗可以改善和稳定晚期恶性肿瘤患者疗效,不良反应少,其安全性高,临床应用上具有较好的前景。
Objective To observe the safety of recombinant human endostatin injection (Endo) combined with chemotherapy in the treatment of advanced lung adenocarcinoma. Methods Twenty-four patients with advanced lung adenocarcinoma diagnosed by histopathology or cytology were selected. The recombinant human endostatin injection 15 mg added to 500 mL of normal saline slow intravenous infusion, the first to 14 days of continuous administration, intermittent 7 d repeat, while the combination of NP chemotherapy drugs every 21 d for a cycle. Adverse reactions and effects were evaluated after 2 cycles of treatment. Results After 24 cycles of treatment, there were 0 cases of complete remission (CR), 7 cases of partial remission (PR), 13 cases of stable (SD) 13 cases (54%) and 4 cases of progression (PD) (17%). The effective rate (RR) was 29%, and the clinical benefit was 83%. There were 4 grade Ⅲ adverse reactions including gastrointestinal reaction (1/24) and thrombocytopenia (3/24). Conclusion Recombinant human endostatin injection combined with NP chemotherapy can improve and stabilize the efficacy of advanced malignant tumor patients with fewer adverse reactions, high safety and good clinical application.